Gregory Vidal, MD, PhD

Articles

Treatment Planning for HER2+ Breast Cancer: The Role of Ovarian Function Suppression

April 28th 2025

Panelists discuss how ovarian suppression combined with endocrine therapy shows benefits for premenopausal patients with triple-positive breast cancer, particularly in younger, high-risk populations.

Optimizing Therapy in HR+/HER2+ Breast Cancer: Balancing Endocrine, HER2-Targeted, and Chemotherapy Options

April 28th 2025

Panelists discuss how treatment strategies for triple-positive breast cancer (hormone receptor [HR] positive and HER2 positive) differ from those for hormone receptor–negative, HER2-positive disease, with emphasis on balancing endocrine therapy, HER2-targeted therapy, and chemotherapy.

Looking Towards The Future of HR+/HER2- Breast Cancer

August 22nd 2023

The expert panel discusses ongoing research and offers closing thoughts on the future of HR+/HER2- breast cancer treatment.

Practical Considerations for ADC Selection in HR+/HER2- mBC

August 22nd 2023

Panelists share clinical insight into how to approach treatment selection among ADCs in HR+/HER2- metastatic breast cancer both now and in the future, given the currently available options and additional ADCs in development.

Data Updates on Sacituzumab Govitecan

August 15th 2023

Dr Gadi discusses recent data updates on the TROP-2–directed antibody-drug conjugate (ADC) sacituzumab govitecan (SG), including analyses performed in patients with HER2-low disease.

Biomarker Testing Practices in HR+/HER2- Breast Cancer

August 15th 2023

Experts on HR+/HER2- breast cancer discuss biomarker testing approaches, including sampling considerations and timing of testing.

HR+/HER2- Breast Cancer: Inhibiting the PI3K/AKT/mTOR Pathway

August 8th 2023

Dr Vidal expands on use of PI3K/AKT/mTOR pathway inhibitors following frontline progression, focusing on the PI3K inhibitor alpelisib for patients with PIK3CA mutations, as well as capivasertib, an AKT inhibitor in development.

Addressing Disease Progression on ET: Data Updates and Ongoing Trials

August 8th 2023

A focused discussion on trials that may address disease progression on first-line therapy, including those on ET and CDK4/6 inhibitor rechallenge and novel combination strategies.

Potential Approaches to Treatment Switching in HR+/HER2- mBC

August 1st 2023

Experts share how they approach management of patients with disease progression on first-line endocrine therapy, with a focus on ESR1 mutation testing and identifying who might be suitable for treatment with the oral SERD elacestrant.

Ribociclib/ET versus Chemotherapy in Premenopausal Patients: RIGHT Choice

August 1st 2023

Timothy Pluard, MD, discusses recent data from an age-based subgroup analysis of RIGHT Choice, which compares the efficacy of combination ribociclib/ET versus chemotherapy in the first-line treatment of HR+/HER2- advanced breast cancer.

The SONIA Trial: Exploring CDK4/6 Inhibitor Efficacy in the First- and Second-Line Settings

July 25th 2023

Gregory Vidal, MD, PhD, presents ASCO 2023 data from the SONIA trial, which assessed the efficacy of CDK4/6 inhibitors when given as part of a combination with endocrine therapy (ET) in either the first- or second-line setting.

Real-World Data on CDK4/6 Inhibitors in HR+/HER2- Metastatic Breast Cancer and Ongoing Trials

July 25th 2023

Experts on HR+/HER2- breast cancer review recent real-world data on CDK4/6 inhibitors and share excitement about first-line trials that have not yet read out.

CDK4/6 Inhibitors in the Metastatic Breast Cancer Setting

July 18th 2023

The expert panel reviews CDK4/6 inhibitor options in the HR+/HER2- metastatic breast cancer (mBC) setting and previous data supporting their use.

Treatment and Dose Optimization in HR+/HER2- Early Breast Cancer

July 18th 2023

A comprehensive discussion on approaches to optimizing treatment selection and dosing in HR+/HER2- breast cancer.

Managing Abemaciclib-Associated Toxicities in HR+/HER2- Early Breast Cancer

July 11th 2023

VK Gadi, MD, PhD, shares his strategies for managing adverse events related to abemaciclib in the treatment of HR+/HER2- breast cancer.

Recent Data on Adjuvant Therapies in HR+/HER2- Breast Cancer

July 11th 2023

Experts on HR+/HER2- breast cancer review data updates on adjuvant therapies from the 2023 ASCO Annual Meeting.

Circulating Tumor DNA as a Prognostic Marker in HR+/HER2- Breast Cancer

July 4th 2023

A discussion on the use of circulating tumor DNA (ctDNA) as a prognostic biomarker in HR+/HER2- breast cancer.

Recent Data on Neoadjuvant Therapy in HR+/HER2- Breast Cancer

July 4th 2023

The expert panel reviews data updates on neoadjuvant therapy in HR+/HR2- early breast cancer and discusses the role of CDK4/6 inhibition in this setting.

Unmet Needs in Early-Stage HR+/HER2- Breast Cancer

June 27th 2023

Experts on HR+/HER2- breast cancer discuss unmet needs in the early-stage setting.

Standard-of-Care Treatment Approaches for HR+/HER2 Early Breast Cancer

June 27th 2023

A panel of expert oncologists review standard-of-care treatment approaches for HR+/HER2- early breast cancer and genetic testing practices when utilizing PARP inhibitors.